All data are based on the daily closing price as of July 9, 2025
a
ALTEOGEN
196170.KQ
307.71 USD
1.51
+0.49%
Overview
Last close
307.71 usd
Market cap
16.40B usd
52 week high
318.01 usd
52 week low
53.69 usd
Target price
410.52 usd
Valuation
P/E
N/A
Forward P/E
N/A
Price/Sales
147.251
Price/Book Value
60.6282
Enterprise Value
15.99B usd
EV/Revenue
145.1545
EV/EBITDA
266.7012
Key financials
Revenue TTM
110.19M usd
Gross Profit TTM
78.30M usd
EBITDA TTM
52.32M usd
Earnings per Share
N/A usd
Dividend
N/A usd
Total assets
441.26M usd
Net debt
N/A usd
About
ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. The company develops ALT-P1, a long-acting human growth hormone that is in the Phase IIa clinical trial; and ALT-Q2, a long-acting active form of coagulation factor VII for the treatment of hemophilia based on its NexP technology. It is also involved in the development of ALT-P7, a targeted breast/gastric cancer drug that is in the Phase I clinical trial; ALT-Q5, an antibody-drug conjugate (ADC) for the treatment of ovarian cancer based on its NexMab ADC technology; and ALT-LS2, a SC (subcutaneous) formulation of trastuzuamb for the treatment of breast and gastric cancer. The company has a strategic alliance with Kissei Pharmaceutical for the development of ALT-L9, a biosimilar of Eylea (Aflibercept) which is currently under Phase 1 trial; and Cristalia for the development of ALT-L2, a biosimilar of Herceptin (Trastuzumab), a monoclonal antibody for the treatment of breast cancer, which is in the Phase II clinical trial. ALTEOGEN Inc. was founded in 2008 and is headquartered in Daejeon, South Korea.